This is a working overview of lyophilized powder, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Supplied material is typically a lyophilized white to off-white powder. The peptide is freely soluble in water and in common aqueous buffers, which allows it to be handled as a stock solution. Because the sequence contains no cysteine, disulfide cross-linking is not a route of degradation. The absence of aromatic residues means ultraviolet absorbance at 280 nm is minimal, so quantification usually relies on peptide bond absorbance near 214 nm or on amino acid analysis.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
During the Edo period of Japan, the consumption of polished white rice, once largely restricted to the upper classes, began to spread among lower-ranking samurai and urban townspeople, often forming the bulk of their diet with few side dishes. This dietary shift contributed to the rising prevalence of beriberi, particularly in major cities such as Kyoto, Nagoya, Edo (modern Tokyo), and Osaka by the late 17th century. In contrast, rural populations and farmers, who relied on mixed grains and less refined brown rice with higher thiamine content, were largely spared from the disease. With the onset of the Meiji era and its accompanying economic growth, refined white rice became more widely accessible across social classes. The resulting popularization of a polished white rice diet contributed to the nationwide spread of beriberi, which came to be regarded as a disease endemic to Japan.
== Businesspeople == Henry Rutgers (1766), Revolutionary War hero, businessman, philanthropist, and namesake of Rutgers University Leffert Lefferts (1794), first president of Long Island Bank William Bard (1798), son of physician Samuel Bard, founder and first president of New York Life Insurance Company Stephen Price (1799), theatrical manager who managed Park Theatre in Manhattan and Theatre Royal, Drury Lane in London William Backhouse Astor Sr.* (1811), son of John Jacob Astor Cornelius Roosevelt* (attended, year unknown), member of the Roosevelt family, one of the founders of the Chemical Bank; great-grandfather of Theodore Roosevelt James H. Roosevelt (1819), founder of Roosevelt Hospital Robert Goelet Sr. (1828), banker and real estate developer who was associated with the founding of the Chemical Bank Bradish Johnson (1831), industrialist involved in the Swill milk scandal Robert L. Cutting (1830), co-founder of the Continental Bank of New York and president of the New York Stock Exchange Henry T. Anthony (1832), photographer, vice-president of the E. & H. T. Anthony & Company Adrian G Iselin* (1837), financier, banker Edward Anthony (1838), photographer and founder of E. & H. T. Anthony & Company, largest manufacturer and distributor of photographic supplies in the U.S. during the 19th century John Jacob Astor III (1839), son of William Backhouse Astor Sr.
== History == Examination of cells in body fluids was historically performed using a hemocytometer, a chamber designed for counting cells microscopically. This technique was limited by poor discrimination between cell types (cells could only be classified as mononuclear or polymorphonuclear) and the low number of cells present in unconcentrated body fluids. Moreover, this technique did not produce a permanent record of the specimen. In a 1966 paper, Watson P. described the first cytocentrifuge, calling it "an apparatus for concentrating cells in suspension onto a microscope slide". The device was sold commercially in the 1970s and in 1983 it was patented by Shandon (now Thermo Scientific). As of 2012, numerous brands of cytocentrifuge exist on the market.
=== No development reported === ADX-71149 (JNJ-1813; JNJ-40411813; JNJ-mGluR2-PAM) – metabotropic glutamate mGlu2 receptor positive allosteric modulator [5] Tebideutorexant (JNJ-61393215; JNJ-3215) – orexin OX1 receptor antagonist [6]
The pharmacology of testosterone, an androgen and anabolic steroid (AAS) medication and naturally occurring steroid hormone, concerns its pharmacodynamics, pharmacokinetics, and various routes of administration. Testosterone is a naturally occurring and bioidentical AAS, or an agonist of the androgen receptor, the biological target of androgens like endogenous testosterone and dihydrotestosterone (DHT). Testosterone is used by both men and women and can be taken by a variety of different routes of administration.
Sources: en.wikipedia.org
Benfluorex (removed from the market by the EMA due to increased risk of heart disease) Butenolide Diethylpropion FG-7142 Phenmetrazine† (withdrawn in some countries due to the danger of addiction) Phentermine Phenylpropanolamine Pyroglutamyl-histidyl-glycine Sibutramine Other compounds with known appetite suppressant activity include:
== Prognosis == The prognosis for any individual with PFBC is variable and hard to predict. There is no reliable correlation between age, extent of calcium deposits in the brain, and neurological deficit. Since the appearance of calcification is age-dependent, a CT scan could be negative in a gene carrier who is younger than the age of 55. Progressive neurological deterioration generally results in disability and death.
==== Mixed apnea ==== Some people with sleep apnea have a combination of both types; its prevalence ranges from 0.56% to 18%. The condition, also called treatment-emergent central apnea, is generally detected when obstructive sleep apnea is treated with CPAP and central sleep apnea emerges. The exact mechanism of the loss of central respiratory drive during sleep in OSA is unknown but is most likely related to incorrect settings of the CPAP treatment and other medical conditions the person has.
In the past century, there has been much research into the development of effective chiral catalysts due to its great potential in organic synthesis. In the 1960s, cyclometalation reactions including C(sp2)–H and C(sp3)–H cleavage were pioneered by Kleiman, Dubeck, Cope, and Siekman. A decade later, Shaw discovered that inorganic acetate salts promoted otherwise difficult cyclopalladations. To build off of this work, Sokolov focused on developing chiral, enantioenriched metallacyles and proposed the concerted metal-deprotonation (CMD) mechanism. Despite this foundation of discoveries, enantioselective catalysis for C–H functionalization continued to lack in efficiency oand selectivity for desired chiral product formation. In 2008, Jin-Quan Yu reported the first MPAA ligands, showcasing their use in enantioselective activation of C(sp2)–H and C(sp3)–H bonds. Initial synthesis occurred by reacting the nucleophilic amino acid in base with a highly electrophilic acyl chloride resulting in one new amide bond formation. Upon addition of acyl chloride, most resulting groups off of the nitrogen were common protecting groups used in organic synthesis, hence mono-N-protected. Taking advantage of the weak coordination of amides and carboxylates with Pd-complexes, this enantioselective catalysis requires the MPAA ligand to allow the reaction to proceed and determine the product chirality, minimizing side reactions that may occur without the ligand.
The company's primary competitors for its hardware are Nvidia, AMD, Intel, and Broadcom and the company's primary competitors for its cloud computing services are Amazon Web Services, Microsoft Azure, Google Cloud Platform, Oracle Corporation, and CoreWeave.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.